JP2018502083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502083A5 JP2018502083A5 JP2017533635A JP2017533635A JP2018502083A5 JP 2018502083 A5 JP2018502083 A5 JP 2018502083A5 JP 2017533635 A JP2017533635 A JP 2017533635A JP 2017533635 A JP2017533635 A JP 2017533635A JP 2018502083 A5 JP2018502083 A5 JP 2018502083A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- fluoroalkyl
- deuteroalkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 125000005345 deuteroalkyl group Chemical group 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103033P | 2015-01-13 | 2015-01-13 | |
| US62/103,033 | 2015-01-13 | ||
| PCT/US2016/012909 WO2016115054A2 (en) | 2015-01-13 | 2016-01-11 | Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502083A JP2018502083A (ja) | 2018-01-25 |
| JP2018502083A5 true JP2018502083A5 (enExample) | 2019-02-14 |
| JP6764866B2 JP6764866B2 (ja) | 2020-10-07 |
Family
ID=56406559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533635A Expired - Fee Related JP6764866B2 (ja) | 2015-01-13 | 2016-01-11 | Ｃａ２＋放出活性化Ｃａ２＋（ＣＲＡＣ）チャネルのモジュレーターおよびその薬学的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10213412B2 (enExample) |
| EP (1) | EP3245189B1 (enExample) |
| JP (1) | JP6764866B2 (enExample) |
| CN (1) | CN107207431B (enExample) |
| AU (1) | AU2016207014B2 (enExample) |
| CA (1) | CA2969814C (enExample) |
| ES (1) | ES2825798T3 (enExample) |
| MX (1) | MX379440B (enExample) |
| WO (1) | WO2016115054A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6764866B2 (ja) | 2015-01-13 | 2020-10-07 | ビブレオン バイオサイエンシーズ，エルエルシー | Ｃａ２＋放出活性化Ｃａ２＋（ＣＲＡＣ）チャネルのモジュレーターおよびその薬学的使用 |
| WO2019077496A1 (en) * | 2017-10-17 | 2019-04-25 | Rhizen Pharmaceuticals Sa | CRAC CANAL MODULATORS FOR THE TREATMENT OF ESOPHAGE CANCER |
| EA202090682A1 (ru) * | 2017-10-30 | 2020-10-15 | Ризен Фармасьютикалз Са | Модуляторы кальциевых каналов, активируемых высвобождением кальция, для лечения гематологических и солидных раковых заболеваний |
| EP3849552A1 (en) | 2018-09-14 | 2021-07-21 | Rhizen Pharmaceuticals AG | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| BR112022018480A2 (pt) * | 2020-03-16 | 2022-11-29 | Zomagen Biosciences Ltd | Moduladores de nlrp3 |
| CA3179405A1 (en) * | 2020-05-20 | 2021-11-25 | Kenneth A. Stauderman | Methods and compositions for treating acute kidney injury |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4644009A (en) * | 1984-10-29 | 1987-02-17 | Usv Pharmaceutical Corporation | Aryl-alkyl heterocyclic compounds |
| US5041442A (en) * | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
| US5985935A (en) * | 1992-03-06 | 1999-11-16 | Statens Seruminstitut | Treatment and prophylaxis of diseases caused by parasites, or bacteria |
| DE69529056T2 (de) | 1994-01-19 | 2003-11-13 | Sankyo Co., Ltd. | Pyrrolopyridazin-derivate |
| JP3143571B2 (ja) * | 1994-01-19 | 2001-03-07 | 三共株式会社 | ピロロピリダジン誘導体 |
| JP2000256358A (ja) * | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| KR20070057965A (ko) * | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| US7951794B2 (en) * | 2005-06-24 | 2011-05-31 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| TW201130488A (en) * | 2010-02-03 | 2011-09-16 | Daiichi Sankyo Co Ltd | Pyrrole compound |
| HRP20161412T1 (hr) * | 2011-06-27 | 2016-12-02 | Newron Pharmaceuticals S.P.A. | Fluorirani derivati arilalkilaminokarboksamida |
| AU2014282886A1 (en) * | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| JP6764866B2 (ja) | 2015-01-13 | 2020-10-07 | ビブレオン バイオサイエンシーズ，エルエルシー | Ｃａ２＋放出活性化Ｃａ２＋（ＣＲＡＣ）チャネルのモジュレーターおよびその薬学的使用 |
-
2016
- 2016-01-11 JP JP2017533635A patent/JP6764866B2/ja not_active Expired - Fee Related
- 2016-01-11 EP EP16737683.9A patent/EP3245189B1/en active Active
- 2016-01-11 ES ES16737683T patent/ES2825798T3/es active Active
- 2016-01-11 MX MX2017009164A patent/MX379440B/es unknown
- 2016-01-11 CA CA2969814A patent/CA2969814C/en active Active
- 2016-01-11 AU AU2016207014A patent/AU2016207014B2/en not_active Ceased
- 2016-01-11 CN CN201680005731.2A patent/CN107207431B/zh active Active
- 2016-01-11 WO PCT/US2016/012909 patent/WO2016115054A2/en not_active Ceased
- 2016-01-11 US US15/539,088 patent/US10213412B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502083A5 (enExample) | ||
| JP2019163290A5 (enExample) | ||
| JP2010519206A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| HRP20171610T1 (hr) | Selektivni inhibitori pi3k delta | |
| JP2020537657A5 (enExample) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| JP2017501234A5 (enExample) | ||
| JP2012504604A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2019515043A5 (enExample) | ||
| JP2011016800A5 (enExample) | ||
| JP2013525433A5 (enExample) | ||
| JP2017516785A5 (enExample) | ||
| JP2019518071A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2013536259A5 (enExample) | ||
| JP2017538773A5 (enExample) | ||
| CA2704724A1 (en) | 5use of a peptide as a therapeutic agent | |
| JP2019515952A5 (enExample) | ||
| JP2003531103A5 (enExample) |